The Single-cell Genome Sequencing size is estimated to reach $9 billion by 2030, growing at a CAGR of 16.2% during the forecast period 2023-2030. Single-cell genome sequencing is one of the major areas of research for finding a cure for chronic ailments such as cancer. The rising cases of cancer worldwide would drive the Single-cell Genome Sequencing Market during the forecast period. According to Cancer.org, the global burden of new cancer cases would grow to 27.5 million by 2040. This would certainly boost the demand for Single-cell Genome Sequencing Market to find a cure for such chronic diseases.
Rapid development in sequencing technologies is also expected to drive the growth of this market during the forecast period. Polymerase chain reaction (PCR) and next-generation sequencing are emerging as the preferred technologies for various applications, especially for single-cell genomic sequencing. In January 2022, a group of medical Scientists at Stanford and their collaborators developed a new ultra-fast genome sequencing approach that offered a diagnostic rate of about 12% higher than the average rate for diagnosing mystery illnesses.
Market Snapshot : Single-cell Genome Sequencing Market - Report Coverage:
The “Single-cell Genome Sequencing Market Report- Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Single-cell Genome Sequencing Market.
COVID-19 / Ukraine Crisis - Impact Analysis:
- The COVID-19 pandemic had a positive impact on the Single-cell Genome Sequencing Market. The studies on single-cell genome sequencing offered critical insights into coronavirus infection and allowed medical experts better understand the nature of the infection. On performing single-cell sequencing, most cell types in patients with COVID-19 showed a significant interferon-α response along with an overall acute inflammatory response.
- Russia’s invasion of Ukraine has made a significant impact on the Single-cell Genome Sequencing market. It has not only affected the lives and work of genomic researchers in these countries but has also influenced the relationships with colleagues in the U.S. and elsewhere.
- The sanctions against Russia are most likely to bring experimental genomics research in the country to a halt. Ukraine had several genomics research projects going on before the war began. Now, with all the unrest, most researchers in Ukraine are fleeing the country and looking for positions in the west.
Key Takeaways:
- Fastest Growth in the Asia-Pacific Region : Geographically, in the global Single-cell Genome Sequencing market share, Asia-Pacific is analyzed to grow with the highest CAGR of 17.2% during the forecast period 2023-2030. This growth is driven by the rising number of cancer cases in the region. According to the projections by the International Agency for Research on Cancer, there would be about 15.1 million new cases per year in Asia until 2040. The unprecedented rate of population aging is the key determinant of this development. Japan, the country with the oldest population in the world, also has the highest rate of cancer. This would drive growth in the Single-cell Genome Sequencing Market in the region during the forecast period.
- Reagents Segment to Register the Fastest Growth : In the Single-cell Genome Sequencing analysis, the Reagents segment is estimated to grow with the highest CAGR of 17% during the forecast period. This is because the use of single-cell sequencing reagents allows the experts to process bulk samples with the input of as few as 100 cells. With the recent advancements in single-cell DNA sequencing techniques, bulk DNA sequencing can be done more efficiently and cost-effectively. Moreover, commercial reagents are now available for all the wet-lab steps of a scRNA-seq protocol as well as for preparing barcoded cDNA libraries. The increasing availability of reagents and their growing need in various single-cell genome sequencing processes are boosting its growth in the Single-cell Genome Sequencing Market during the forecast period.
- Academic and Research Laboratories Segment is Leading the Market : According to the Single-Cell Genome Sequencing Market forecast, the academic and research laboratories segment held the largest market share of 38.6% in 2022. Single-cell genomics is emerging as one of the major areas in scientific research and development. The rising prevalence of chronic diseases demands new cures and treatment options, which is further boosting the growth of the academic and research laboratories segment. Moreover, understanding the genomics of individual cells opens up a new set of opportunities for the world of biotechnology.
- Increased Funding for Vaccine Development and Production : Government agencies in various parts of the world have increased funding for the development and production of vaccines in response to the pandemic. This has led to increased use of single-cell analysis (SCA) tools for COVID-19 research. SCA helps in the assessment of the peripheral immune function of the disease and contributes to the study of the pathophysiology and treatment possibilities of the disease. Thus, the market is positively impacted by COVID-19.
- Massive Demand in the field of Immunology, Oncology and Others : Single-cell technology is used in the molecular-level examination of processes and pathways of cellular heterogeneity along with its assessment. This rapidly developing technology has major applications in immunology, oncology and other major areas. Moreover, the development of advanced tools that help make proteomic and transcriptomic processes simpler is also driving the use of single-cell analysis methods, boosting the growth of the Single-cell Genome Sequencing Market.
- High Cost of Instruments to Hinder Market Growth : While there is a significant demand for genome sequencing machines among the end-user industries, the instrument costs are significantly high. According to a report published in Bloomberg, Illumina’s new NovaSeq X series costs $985,000 for the base machine and $1.25 million for the advanced one. Such high cost of instruments are likely to hinder the growth of the Single-cell Genome Sequencing Market.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Single-Cell Genome Sequencing Market.
The top 10 companies in this industry are listed below:
- Standard BioTools Inc. (Maxpar®, Advanta™ Assays)
- QIAGEN N.V. (QIAseq FX, REPLI-g)
- Illumina, Inc. (NovaSeq, NextSeq)
- F. Hoffmann-La Roche AG (AVENIO, MagNA Pure)
- Thermo Fisher Scientific, Inc. (Invitrogen, Applied Biosystems)
- Bio-Rad Laboratories, Inc. (SEQuoia, ddSEQ)
- 10X Genomics, Inc. (Chromium, Visium)
- Becton, Dickinson and Company (BD Rhapsody™, BD AbSeq)
- Oxford Nanopore Technologies Limited (MinION, GridION)
- Beijing Genomics Institute Group (CardioGen, COLOTECT™)
#SingleCellSequencing #Genomics #PrecisionMedicine #DNASequencing #GenomeResearch #Biotechnology #LifeSciences #NextGenSequencing #HealthcareInnovation #MolecularBiology
